Midkine (MK) is a heparin-binding growth factor that promotes the growth, migration, and survival of various cells. Its overexpression has been observed in many human malignancies, making it an attractive therapeutic target.METHODS.
We established a human midkine blockade system involving RNA interference.RESULTS.
The synthetic small interfering RNA (siRNA) targeting human midkine almost completely inhibited the secretion of midkine by a human prostate cancer cell line, PC-3, and consequently suppressed the proliferation and anchorage-independent growth of the transfected cells. The midkine siRNA, together with atelocollagen, significantly suppressed the growth of PC-3 tumors, which had been subcutaneously xenografted. These inhibitory effects of midkine siRNA were augmented by combinational treatment with a chemotherapeutic, paclitaxel (PTX), both in vitro and in vivo. The dose of PTX (12 mg/kg) used for the combinational treatment did not cause leukopenia or liver damage, which are often reported as serious adverse effects of PTX. The effect of the combination on tumor growth was comparable with that of PTX alone at higher doses that have exhibited severe adverse effects. Midkine siRNA suppressed mainly cell proliferation and slightly angiogenesis, whereas PTX enhanced apoptosis and slightly suppressed angiogenesis. The combination treatment was particularly effective for suppression of angiogenesis; consequently, it had striking effects on all aspects (proliferation, apoptosis, and angiogenesis).CONCLUSIONS.
We established a novel and safe cancer therapy strategy involving midkine siRNA combined with PTX, with less adverse effects.CONCLUSIONS.
The authors showed a therapeutic strategy against prostate cancers involving RNA interference against human midkine (MK), a heparin-binding growth factor, which is overexpressed in human prostate cancers. Downregulation of MK with a synthetic small interfering RNA (siRNA) inhibited tumor growth in human prostate cancer (PC-3) xenografts, and antitumor activity of the siRNA in mice was augmented when combined with paclitaxel. We can reduce the dosage of a chemotherapeutic in combination with a molecular targeting therapeutic consisting of nucleic acids, especially based on RNA interference.